A new Nature study reports durable T cell immunity from personalized mRNA vaccines in adjuvant triple-negative breast cancer (TNBC), addressing a high-recurrence population with limited targeted therapy options.news
This early signal highlights the potential of neoantigen-specific immunotherapy to improve long-term outcomes, pending validation in larger trials.
Nothing published in the last 14 days cleared the bar. Below is the most relevant background we're tracking.
Relevant work from earlier we're still surfacing — not today's news.